Patient selection. This study reviews the clinical observations on 177 patients. Data for 113 patients are reviewed from published reports: 10 studies have published concise case descriptions of 38 patient^'^-^^; three other studies have discussed 75 patients, providing data on age, sex, and family background, and describing the major bleeding complications.26.28 Sixty-four patients, representing 5 1 individual families, have been studied in Paris, France, during the past 33 years at the Hopital Lariboisiere under the direction of Professor Jacques Caen (Table 1) . Clinical summaries on 18 of these patients have been published p r e v i o~s l y . ' .~~.~~ Many observations in this review were only possible because of the complete data available on the patients studied in Paris.
When this group of 64 patients is discussed separately to make a particular point, they are referred to as "the Paris patients." All patients were diagnosed by the presence of a normal platelet count, normal platelet morphology, a long bleeding time, absent or severely diminished platelet aggregation by adenosine diphosphate and other agonists, normal platelet agglutination by ristocetin, and normal plasma coagulation studies. Clot retraction was absent or severely diminished in the patients classified as type I in Table 1 , it was present in the patients classified as type 11, and it varied from absent to normal in the patients classified as variants. These criteria allow the diagnosis of thrombasthenia to be made quickly and definitively in a routine clinical laboratory.
The rarity of this disease and its uneven geographic distribution is demonstrated by the fact that only 12 of the 177 patients have been reported from the United States.18*19*21~22s24 Fiftyfive patients were from Israel and J~r d a n ,~~*~' * '~ and 42 from South India.26 The cause for this uneven distribution is the frequent occurrence of intermarriage in these regions, allowing expression of autosomal recessive traits and suggesting a rare occurrence of asymptomatic heterozygous subjects. The frequency of consanguinity among 84 patients from the literature, for whom data were available, was 67%. The 64 Paris patients represented a diverse genetic spectrum since only 2 of these 51 families (families 16 and 17, Table 1 ) 3 0 9 3 1 are known to be related to one another, yet the frequency of consanguinity was high (39%). The association of thrombasthenia with consanguinity is further emphasized by the observation that 10 of the families studied in Paris were of North African or Middle Eastern origin and three families were gypsies, in whom intermarriage may be an accepted custom. Therefore, although Glanzmann's thrombasthenia is typically a rare disorder, it can be almost as frequent as The average age (at the time of the latest examination or of the literature report) of the 113 patients for whom age was known was only 20. Most patients were diagnosed before age 5, many a t birth or during early Because the mortality of thrombasthenia is low, the young age reflects the recent era in which the diagnosis has been established and the minimal symptoms in most adults. It would be of interest to know if patients with thrombasthenia are protected from atherosclerotic disease,
Patient age.
infancy. since platelets have a postulated role in the pathogenesis of atheroscler~sis~~ and therapeutic inhibition of platelet GP IIb-IIIa function prevents t h r o m b~s i s .~~'~~ There are no reports of myocardial infarction or stroke in patients with thrombasthenia, but only 5 of these 177 patients were over 50 years old, therefore little or no thrombotic disease would be expected.
Among the 1 13 patients from the literature, 60 (53%) were female, consistent with the known autosomal inheritance. The proportion of females among the Paris patients (66%) was greater than expected, probably re-
Patient sex.
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From The 6 4 patients representing 5 1 families are presented who have been studied in Paris at the Hopital Lariboisiere under the direction of Professor Jacques Caen. Siblings are listed with the same number. The patient's age represents the age at the time of the latest evaluation. Platelet GP Ilb-llla was measured by CIE, Western blot, and/or MoAb binding and the results are given as the percent of normal. The method of GP measurement on the individual patients is identified by the suprascript notation: *, CIE + WB; t, CIE + Western blot (We) + MoAb binding (MAb); $, WB only; 8, CIE + MoAb; 1 1 , MoAb only; 7, CIE only. Two values are given for patient 47 because his platelet GP Ilb-llla content was estimated to be 20% by MoAb binding to unstimulated platelets, but to be 50% by CIE and MoAb binding to thrombin-activated platelets.'* Patients in whom these measurements were not performed were classified as types I or I 1 as described in the text. Siblings were assumed to share the same degree of GP Ilb-llla deficiency when no direct measurements were performed. Major clinical events are noted. Although many descriptions seem redundant, they emphasize the common clinical features of thrombasthenia, while other observations emphasize the discrepency between the severity of GP Ilb-llla deficiency and the bleeding manifestations. In the clinical descriptions, transfusion refers only to the transfusion of red cells or whole blood. All patients received either red cell or platelet transfusions, given for bleeding episodes or before procedures, except patients 47 and 50. References are given where the original data from studies on each patient are reported. These patients were referred by the following physicians: Dr Bellucci, Professor Tobelem, and Professor Caen Abbreviations: GI, gastrointestinal; GVHD, graft-versus-host disease.
thrombocytopenic purpura, does not occur. The exception to this rule was that 7 of the 64 Paris patients presented with diffuse petechial hemorrhage a t birth (patients lb, 4, 16b, 20, 27,28a, 35) and neonatal purpura was also described in 9 of 22 patients reported from IsraeLz3 This is likely to be related to the petechial hemorrhages that can be found by careful inspection of most normal newborn infants, apparently caused by compression during vaginal delivery and the resulting increased venous pressure. Two studies found petechiae in half (173 of 348) of normal neonates.38s39 Therefore, the neonatal purpura in thrombasthenic infants can be considered the result of greater susceptibility to birth trauma. This is consistent with the observation that purpura in older children and adults is related to minor trauma, and that spontaneous petechiae are rare. Epistaxis is the most common cause of severe bleeding in
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From Data are from 113 patients presented in the literature,'6-28 and 64 patients presented in Table 1 . The frequency of each type of bleeding in the patients reviewed from the literature was often noted only in concise comments or tables, and may represent only the more prominent symptoms. The actual occurrence of purpura, epistaxis, and gingival bleeding may be nearly universal among these patients if careful observations are performed over a long time. As discussed in the text, it is not clear if spontaneous hemarthrosis, intracranial hemorrhage, or visceral hematomas occur. When these hemorrhages were fully described, a predisposing cause was apparent or suspected.
'Information was not available for all patients.
thrombasthenia. The common childhood habit of nose picking, combined with the vulnerability of the superficial, rich plexus of arterioles located between bone or cartilage and delicate mucosa, makes epistaxis a very common phenomenon in normal ~h i l d r e n .~' .~~ In thrombasthenia, epistaxis is typically more severe in childhood, an exaggeration of the very frequent occurrence of mild epistaxis among normal children between ages 4 through 10.41.42 Severe epistaxis is unusual in adult patients, and this may be the primary reason for the impression that the risk of bleeding in thrombasthenia decreases with age.'^^,'^ For example, Paris patients 12a, 12b, 44, and 46 had 1 to 3 episodes of severe epistaxis requiring red cell transfusions between ages 4 through 10, but they have had no significant bleeding and no transfusions in the 25 to 35 years since (Table 1) . However, the inevitable exceptions are illustrated by patient 23c, who had minimal epistaxis as a child but then had 10 episodes, each requiring red cell transfusion, when he was 35 years old; and patient 39, who has had frequent severe epistaxis only since age 22 (Table 1) .
Gingival bleeding is another constant feature. It is often a reflection of poor dental hygiene, and is less common in patients who have regular and thorough dental care. Gingival bleeding is rarely associated with major acute blood loss, but it is a common cause of iron deficiency.
Menorrhagia is a critical hemorrhagic problem. Bleeding at menarche represents a particular risk, and was severe enough to require transfusions in most patients. This is consistent with the prolonged proliferative estrogen stimulation of the initial anovulatory cycles, that can cause greater and more prolonged bleeding with the first menstrual periods in normal adolescent More severe hemorrhage with the initial menstrual periods is another physiologic explanation for the apparent greater risk of bleeding in younger patients. Only one patient is specifically described as having normal menstrual bleeding at menarche."
Hemorrhage of any other type was rare. Consistent with the mucocutaneous pattern of bleeding in thrombasthenia, gastrointestinal hemorrhage may occur, and appears to be a greater risk among young children. Hematuria has occurred in 10 of the 177 patients. Hemarthrosis has been reported in five patients: in four the circumstances were not described23326; the Paris patient 32 developed hemarthrosis of her knee a t age 10 after trauma while playing soccer. Only three patients have had intracranial hemorrhage: one case was not described,26 the other two were among the Paris patients. Patient 30a had a meningeal hemorrhage after head trauma as a child, and patient 49 had an intracerebral hematoma after a fall at age 6 , which required surgical evacuation. It is important to note that spontaneous deep visceral hematomas that are characteristic of disorders of coagulation, such as retroperitoneal hematomas, have not been observed except for the intrahepatic hematoma that occurred in patient l a (described below).
Spontaneous, unprovoked bleeding is actually uncommon in Glanzmann's thrombasthenia. Severe bleeding typically occurred in association with physiologic or pathologic conditions that cause bleeding in normal subjects. Neonatal purpura, childhood epistaxis, gingival bleeding associated with poor dental hygiene, and menorrhagia at menarche could all be described as exaggerations of normal bleeding. Bleeding after trauma or surgical procedures may also be severe. In one series, 10 of 12 infants undergoing circumcision without preparative platelet transfusion had excessive bleeding,28 and 3 of 11 patients in another series were first diagnosed because of hemorrhage a t c i r c~m c i s i o n .~~ Tooth extractions without platelet transfusions are commonly associated with excessive bleeding:' and bleeding can be severe even with the spontaneous loss of deciduous teeth.
Pregnancy and delivery represent a particularly severe hemorrhagic risk in women with thrombasthenia. In normal women, blood flow to the placenta at term is estimated to be 600 mL/min, and this must be staunched promptly a t the time of placental ~eparation.~' The most effective hemostatic control mechanism at delivery is uterine contraction to obliterate the lumens of the severed arterioles and veins.47 Despite normal hemostasis, normal women lose an average of 500 mL of blood at vaginal delivery, and 900 mL at cesarian ~ection.~' Therefore, the risk for hemorrhage in thrombasthenia is obvious. Pregnancy itself is not a serious risk; vaginal bleeding severe enough to require transfusions occurred only once in 21 pregnancies (Table 3) . Two other patients had complications of pregnancy without excessive bleeding. Delivery was complicated by severe hemorrhage on 6 of 19 occasions. All 13 uncomplicated deliveries were performed after a platelet transfusion, and platelet transfusions were commonly continued for up to 6 days postpartum. Platelet transfusion did not always prevent severe vaginal hemorrhage, which occurred as late as 13 days after delivery (Paris patient 40), and recurred up to 4 weeks later.23 For example, one of the Paris patients (patient 40) was transfused with platelets before a normal vaginal delivery and then kept in the hospital without complications for 9 days, but lifeFor personal use only. on July 14, 2017. by guest www.bloodjournal.org From Twelve patients are from the Paris group and they are referred to by their number in Table 1 threatening uterine hemorrhage, to a hematocrit of 12%, began at home on the 13th postpartum day. None of six patients delivered by cesarian section, with platelet transfusions continued until wound healing was complete, suffered from excessive bleeding. Even though normal women lose almost a liter of blood with an uncomplicated cesarian section, twice as much as with a vaginal delivery,"' this operative procedure may avoid the complication of adherent pieces of placenta or the accumulation of large blood clots that can inhibit uterine contraction. Uterine contraction is stimulated by a rapid infusion of oxytocin as soon as the infant's shoulder is delivered, and full contraction for effective hemostasis can be directly ~bserved.~'
In contrast to the well-defined nature of the bleeding in thrombasthenia, the severity of bleeding was not predictable. Thrombasthenia is certainly a severe hemorrhagic disease, as 54 (84%) of the Paris patients have required red cell transfusions. However, some patients have never had serious bleeding, and most have been healthy and free of bleeding complications throughout their adult lives. The unpredictability of severe hemorrhage is best illustrated by the inconsistency between siblings, who presumably share the same genetic defect. For example, patient 10a has never required a red cell transfusion and was given platelets only once, when purpura developed during varicella at age 2. In contrast, her brother (patient lob) was the most severely affected among the Paris patients. He had recurrent severe gastrointestinal hemorrhage that was only controlled when an allogeneic bone marrow transplant at age 5 corrected his genetic defect.49 Appreciable differences in the severity of bleeding were also noted between the siblings of families 1, 19, and 26 (Table 1) .
A possible complication of transfusion therapy is the development of an isoantibody against Severity of hemorrhage.
Isoantibody formation.
G P IIb-IIIa, since G P IIb-IIIa on transfused platelets is strongly immunogenic" and it is deficient and/or structurally abnormal in thrombasthenia. However, this has been documented only once among the Paris patients (patient 6),5'-57 even though only two patients (patients 47 and 50) have not been transfused with either red cells or platelets. Patient 6 is one of the least symptomatic patients of the Paris group. He has never required a platelet transfusion and has been transfused with red cells only twice, at ages 38 and 46 (1966 and 1974 ) for a bleeding duodenal ulcer. His isoantibody, presumably stimulated by the presence of platelets in the red cell transfusions, has been persistent but clinically insignificant. This isoantibody reacts with the intact G P IIb-IIIa complex on all normal platelets, and also binds to the dissociated G P IIb polypeptide." Three other thrombasthenic patients have been reported who developed isoantibodies to G P IIb-IIIa, which reacted primarily with G P IIIa.50,58.59 Two further patients may have developed similar isoantib~d i e s .~~.~' Perhaps the presence of some residual platelet G P IIb-IIIa may protect many patients from isosensitization.
MOLECULAR ABNORMALITIES OF PLATELET GP IIB-IIIA
The measurements of G P IIb-IIIa available on the Paris patients are presented in Table 1 . No comparable data are available for the patients reviewed from the literature.
Patients with severe G P IIb-IIIa deficiency (less than 5% of normal) were designated type I (78% of the patients); patients with moderate G P Ilb-IIIa deficiency (10% to 20% of normal) were designated type I1 (14%); and patients with half-normal to normal G P IIb-IIIIa, whose primary defect appeared to be in the receptor function of G P IIb-IIIa rather than a molecular deficiency, were designated as variants (8%). The classification of types I and I1 was originally proposed by Caen in 1972,' before the G P IIb-IIIa abnormality was dis~overed,~ on the basis of platelet fibrinogen content and clot retraction. Because 26 of the 64 patients presented in Table 1 were not studied for their platelet content of G P 1Ib-IIIa, it is assumed that some of these patients may not be accurately assigned. For example, some patients classified here as type I in whom platelet G P IIb-IIIa was not measured could have a variant disorder with dysfunctional G P Ilb-IIIa. Despite these possible inconsistencies, the classification of types I and I1 is a convenient way to describe this group of patients, and it facilitates the comparison of clinical disease with the molecular abnormalities. It is not meant to imply a universal standard for Glanzmann's thrombasthenia, or even the existence of distinct categories of this disease.
Although many type I patients studied by Western blotting demonstrate traces of residual G P IIb and G P IIIa, up to about 10% of none of the patients had more than a trace of intact platelet G P IIb-IIIa complex detectable by crossed immunoelectrophoresis (CIE) or monoclonal antibody (MoAb) binding. Platelets from all type I patients had absent or severely deficient fibrinogen and no or minimal clot retraction. Binding of exogenous fibrinogen was absent or negligible in four patients (patients la, lb, 12a, 12b).64 In contrast, type I1 patients had equivalent amounts of G P IIb and G P IIIa, greater than 10% of normal, present as an For personal use only. on July 14, 2017. by guest www.bloodjournal.org From intact platelet surface G P IIb-IIIa complex, and their platelets were able to bind an equivalent amount of exogenous fibrinogen (10% to 23% of normal in patients 41 and 4264,65). Type I1 patients all had normal or only moderately diminished clot retraction, and substantial amounts of platelet fibrinogen demonstrable by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and measured to be 30% to 58% of normal in patients 41 and 42. 7366 Assuming that a-granule fibrinogen is largely acquired from plasma by megakaryocytes or platelets after surface binding to the G P IIb-IIIa r e~e p t o r , 6~-~~ the presence of platelet fibrinogen in these patients is consistent with the intact fibrinogen receptor function of their residual plasma membrane G P IIb-IIIa. When only SDS-PAGE analysis and platelet function testing were available, patients were designated as type I (patients 24 through 32) or type I1 (patient 44) on the basis of clot retraction and the absence or presence of platelet fibrinogen on SDS-PAGE analyzed samples (eg, see Fig 12, reference 6 or Fig 41-1 , reference 8 for a comparison of family 23, designated "GT 1-3" in the figure, and patient 40, "GT 4"). Eight patients who have not been studied since 1966' were designated as type I (patients 33 through 37) or type I1 (patients 45 and 46) on the basis of absent or present clot retraction. The G P IIb-IIIa concentration of the patients designated as variants was either normal or within the range of asymptomatic heterozygous subjects, and the platelet fibrinogen concentration and clot retraction varied from absent to n~r m a l .~' .~~ Relevant data on patients 49 and 51, who have not been previously published, are discussed below.
CORRELATION OF CLINICAL DISEASE WITH THE PLATELET MOLECULAR ABNORMALITY
Most clinical observations demonstrated no correlation between the amount of platelet G P IIb-IIla and the severity of hemorrhagic disease. This discrepancy is emphasized by the different bleeding symptoms between siblings who presumably share the same genetic defect (discussed above). Eight Paris patients did not present with their first hemorrhagic symptoms until adolescence or adulthood, and four of these patients (patients 6, 15, 24, 33) had severe G P IIb-IIIa deficiency. Patients 38,39,40, and 41, who have 10% to 12% of normal platelet G P IIb-IIIa that can function as a fibrinogen receptor, have had repeated episodes of extremely severe hemorrhage. In contrast, the brothers 12a and 12b are among the least affected of the 64 Paris patients, despite essentially undetectable platelet G P IIb-IIIa and absent platelet fibrinogen binding. All seven of the Paris patients who presented with neonatal purpura had severe G P IIb-IIIa deficiency (type I), suggesting the possibility that at times there may be a correlation between clinical symptoms and the degree of the platelet membrane abnormality.
The Paris patients designated as variant thrombasthenia were heterogeneous both in their molecular and clinical manifestations. Two of these five patients (patients 47 and 50) are the only ones of the Paris group who have never been transfused with either red cells or platelets. Data on these two patients have been p~blished~'~~*: both have about half normal G P IIb-IIIa, half-normal to normal platelet fibrinogen, and normal clot retraction. Patient 48 also has mild disease, has never required a red cell transfusion, and has had two normal pregnancies and vaginal deliveries, but she has no platelet fibrinogen and absent clot retra~tion.~' Data for the other two patients with variant thrombasthenia have not been published. Patient 49 has an abnormality similar to patient 48 (abnormal dissociation of the G P IIb-IIIa complex and absent platelet fibrinogen), but she has had more severe bleeding complications. Patient 5 1 has absent platelet fibrinogen, absent clot retraction, and severe hemorrhagic disease. In the original description of a family from San Diego with a variant type of thrombasthenia, the patients had a normal platelet content of G P IIb-IIIa, but absent platelet content and binding of fibrinogen and absent clot retraction, and severe hemorrhagic ~ymptoms.'~ Eighteen of the Paris patients with type I thrombasthenia have been studied by Western blot analysis: 15 had detectable G P IIIa and 7 had detectable G P lIb.6' In the patients with only demonstrable G P IIIa, it may exist as a heterodimer complex on the platelet surface with the vitronectin receptor a -s u b~n i t .~'~~~ It has been postulated that the presence of vitronectin receptor function in platelets with residual G P IIIa may partially protect the patients from h e m~r r h a g e .~~
Only two of the Paris families had a complete deficiency of both G P IIb and IIIa by Western blot analysis (families 1 and 2; see Fig 12, reference 7 for an illustration of patient Ib), and therefore would also be deficient in the platelet membrane vitronectin receptor. The two sisters of family 2 both have severe hemorrhagic symptoms. Patient 1 b had severe problems with epistaxis as a child,' but she has had relatively mild disease as an adult and had an uncomplicated pregnancy and delivery. Her sister, patient la, died from complications of an intrahepatic hematoma (described below), but she had minimal bleeding symptoms as a child and did not require transfusion until hemorrhage occurred at menarche. These observations suggest that the absence of the vitronectin receptor does not increase the risk for hemorrhage.
It has been suggested that cells other than megakaryocytes and platelets may be abnormal in Glanzmann's thrombasthenia, and this could be a basis for heterogeneous bleeding symptoms. Because the G P IIIa component of the G P IIb-IIIa complex is present in many tissues as the /3 subunit of the vitronectin r e~e p t o r ,~~-~~ it is possible that an abnormality in the G P IIIa gene may be expressed in cells other than megakaryocytes and platelets. Abnormalities have been reported in fibroblast80-82 and monocyte function.83 However, examination of one thrombasthenic patient with absent platelet G P IIb-IIIa demonstrated normal G P IIIa in vascular endothelial cells, vascular smooth muscle cells, and fibrob l a s t~.~~,~~ One report suggested that normal monocytes contained intrinsic G P IIb-IIIa, which was deficient in a patient with thrombasthenia,86 but subsequent studies demonstrated that G P IIb-IIIa on monocytes was the result of adsorbed platelet membrane fragments or platelet contamination of the monocyte preparati~n.'~.'~ The critical range of G P IIb-IIla concentration can be defined by these clinical observations and by observations on heterozygous subjects. The bleeding problems of the patients For personal use only. on July 14, 2017. by guest www.bloodjournal.org From with type I1 thrombasthenia demonstrate that more than 10% functional G P IIb-IIIa is required to provide adequate hemostasis for severe challenges, such as obstetrical delivery. Heterozygous subjects, who have about half the normal platelet concentration of G P IIb-IIIa, have no significant bleeding, or at most, some minor bruising that is difficult to distinguish from norma1.23,2839039' Because residual G P IIbIIIa is evenly distributed among circulating platelets in thr~mbasthenia,'~ a 50% concentration, but not lo%, must be sufficient for normal hemostasis. Fifty percent G P IIb-IIIa may be required to provide enough fibrinogen binding sites to include the majority of platelets within a developing hemostatic plug. Fifty percent G P IIb-IIIa may also be necessary for normal platelet adhesion to subendothelium at the high shear rates of microvascular blood f l~w .~~.~'
The clinical observation that normal hemostasis can be preserved despite absent platelet fibrinogen binding and aggregation suggests that other platelet functions can compensate for this deficiency. The observation that severe bleeding can occur after events such as childbirth, despite substantial platelet fibrinogen-binding function, suggests that a great hemostatic contribution is required from platelets to meet serious hemostatic challenges.
MANAGEMENT
Management can be described simply as supportive care. The most important measures are to anticipate risks and attempt to prevent bleeding with the judicious use of platelet transfusions. In contrast to normal subjects, in whom the risk of bleeding is best anticipated by the history:6 bleeding in thrombasthenia can be so unpredictable that platelet transfusions before an invasive procedure appear indicated even in patients with minimal past hemorrhagic symptoms. Platelet transfusions should be continued until wound healing is complete. The potential risk of alloimmunization by HLA antigens is the same as in any transfused patient; the special risk of isoantibody formation against G P IIb-IIIa appears to be very rare and not a reason to withhold platelet transfusion. Antifibrinolytic drugs, epsilon aminocaproic acid (EACA) and tranexamic acid:' have been reported to be effective in controlling hemorrhage in thrombocytopenic patients:' but their efficacy in thrombasthenia remains uncertain. Their use is more clearly indicated in the management of teeth extractions (see below). Desmopressin (l-deamino-8-Darginine vasopressin; DDAVP) has been tried in some patients with Glanzmann's thrombasthenia without published evidence of e f f i c a~y .~~, '~~ Local bleeding can almost always be controlled by local measures. For example, epistaxis and gingival bleeding are successfully controlled in most patients by conventional conservative measures with application of gel foam soaked in topical thrombin, or nasal packing."' However, two of the Paris patients (patients 23c and 26a) with recurrent, severe nasal hemorrhage required embolic occlusion of the internal maxillary Regular dental care to carefully clean the teeth and remove plaque is essential to prevent gingival bleeding. Local anesthesia for dental procedures with pericemental injections of lidocaine with l: 100,000 epinephrine can be given without risk of serious bleeding. For teeth extractions, or for hemorrhage accompanying the loss of deciduous teeth, hemostasis can be significantly improved by the application of individually prepared plastic splints that fit snugly over the teeth and gums and provide physical support for hemostasis. Systemic EACA administration has become conventional therapy for managing teeth extractions in patients with hemophilia,'04s105 and it should be used as an adjunct to platelet transfusions in patients with thrombasthenia. A dose of 40 mg/kg four times daily is given, and EACA syrup (25 g/dL) is a convenient form.
Control of menstrual bleeding is a major problem. Severe menorrhagia, usually associated with an excessively proliferative endometrium caused by estrogen dominance, can be effectively treated by a high dose of a 19-norprogesterone, such as norethindrone acetate, 5 mg every 4 hours. Bleeding usually stops within 24 hours, then the dose can be decreased to 5 mg twice a day and continued for 3 weeks. Menstrual bleeding will occur on withdrawal but it should not be severe. Maintenance treatment with birth control pills, such as a combination of 2.5 mg norethindrone acetate and 0.05 mg ethinyl estradiol, should then begin.44i46 More than one pill daily may be required to prevent breakthrough bleeding. Birth control pills control menorrhagia by causing progressively more atrophic endometrium during the initial cycles. In normal women who take birth control pills, menstrual blood loss is typically reduced by
The initiation of birth control pill treatment before the first menstrual period, which predictably causes severe hemorrhage in thrombasthenia, has been suggested but not substantiated as efficacious treatment. Menarche is a late event of puberty, preceded by the adolescent growth spurt and the appearance of breast development and pubic and axillary hair. Therefore, the initial menstrual bleeding could be anticipated and birth control pills started without risk of premature epiphyseal closure.
Finally, the frequent occurrence of iron deficiency anemia must be emphasized. Because as little as 5 mL of blood loss per day, containing 2.5 mg of iron, matches the ability of the intestine to absorb iron,'06 iron deficiency can develop insiduously with only minor bleeding, such as gingival oozing. During periods of rapid growth in infants and adolescents when iron requirements are greater, iron deficiency is expected. Maintenance therapy with oral iron is good practice.
PROGNOSIS
Although thrombasthenia can be a severe hemorrhagic disease, the prognosis should be excellent with careful supportive care. Bleeding problems may be critical, recurrent, and even intractable for periods of time, but when bleeding is controlled and anemia corrected, the patients are normal. Only 2 of the 64 Paris patients (patients l a and 36) have died of hemorrhage. Patient l a was healthy and active until she developed an intrahepatic hematoma. Surgical drainage was required when the hematoma recurred after platelet transfusion therapy, and death followed a complicated hospital course. It is possible that this fatal hemorrhage was related to a hepatic complication of oral contraceptive use: vascular focal nodular hyperplasia, peliosis hepatis, or periportal sinusoidal dilatation. (patients 8, 13, 30, 31, 41, and 46) and seven patients from the literat~re*~.*~.~' had siblings who were thought to have died of hemorrhage. All of these deaths were in children less than 7 years old, four were in infants. The site of hemorrhage was known in nine patients: gastrointestinal bleeding was the cause of death in three patients, and other causes were epistaxis, tongue laceration, hemorrhagic measles, hemorrhage after splenectomy, and hemorrhage after circumcision. However, it is difficult to evaluate the significance of these deaths, as at least five occurred more than 40 years ago and nothing can be determined about the medical care.
The most objective assessment of prognosis is provided by the follow-up of the 15 patients originally described from Paris 23 years ago.' One patient was promptly lost to follow-up and three have died: one from hemorrhage (patient 36) and two in automobile accidents many years ago. The other 11 are well and their disease has minimal effect on their normal daily lives.
LESSONS FROM THROMBASTHENIA FOR OTHER DISORDERS OF HEMOSTASIS
Inherited disorders of platelet function. The clinical bleeding problems of Bernard-Soulier syndrome, an inherited defect of platelet membrane G P Ib-IX and G P V,4*9 appear to be identical to thrombasthenia."' Bleeding may be severe but it is sporadic and often unpredictable. Distinctly different severity of bleeding symptoms between siblings has also been observed in Bernard-Soulier syndrome.' Only three occurrences of hemarthrosis were reported among 54 patients, and two were said to be posttraumatic."' Intracerebral hemorrhage occurred only twice in these 54 patients, and in the one patient in whom the circumstances were described, it was the result of severe trauma."' Whether the bleeding may be more severe in Bernard-Soulier syndrome than in thrombasthenia because thrombocytopenia regularly occurs, with platelet counts as low as 20,000/pL,108,'09 is not clear. The gray platelet syndrome is an inherited defect in ol-granule formation with deficiencies of regulated secretory proteins, such as fibrinogen, von Willebrand factor, and thromb~spondin.~.~.~ It is a rare disorder and the clinical features are not well-described; however, the bleeding symptoms would be expected to be similar to thrombasthenia. The principals of management described for patients with thrombasthenia should be fully applicable to patients with other congenital disorders of platelet function.
With the enormous consumption of aspirin, the frequent hospital use of parenteral P-lactam antibiotics, the ability of many drugs and foods to diminish platelet function, and the occurrence of abnormal platelet function in hematologic and other systemic diseases, acquired abnormalities of platelet function are probably the most common hematologic disorder.Il0 When significant hemorrhage occurs in these patients, it is Acquired disorders of platelet function. often assumed to be related to abnormal platelet function because the bleeding time is prolonged and platelet aggregation is abnormal. However, the contribution of these disorders to clinical bleeding is uncertain, and only with aspirin has an increased risk for significant bleeding been definitively demonstrated."' The clinical experience with thrombasthenia demonstrates that absent platelet aggregation and a prolonged bleeding time are not good predictors of clinical bleeding, and the inability of the bleeding time to predict clinical bleeding was also documented in a recent extensive analysis."* The abnormality of platelet function is typically much more severe in thrombasthenia than in the acquired disorders of platelet function, yet bleeding in thrombasthenia is unpredictable and can be minimal. Therefore, the acquired platelet function defects may often have no or negligible clinical significance.
The etiology of bleeding in systemic diseases that has been postulated to result from abnormal platelet function can be more clearly understood by comparison to the bleeding symptoms in thrombasthenia. For example, patients with chronic renal failure can have bleeding suggestive of abnormal platelet function, such as purpura, epistaxis, and menorrhagia, but other bleeding complications reported in uremic patients do not occur in thrombasthenia: retroperitoneal hematomas, mediastinal hematomas, and hemorrhagic pleural and pericardial effusions."o Therefore, these visceral hemorrhages should be attributed to other hemostatic abnormalities, such as the mucosal lesions of uremia and complications of heparin anticoagulation used for dialysis.
Three patients have been reported with an acquired thrombasthenia caused by autoantibodies against GP IIbIIIa that blocked platelet fibrinogen binding and aggregat i~n . I '~-"~ The clinical bleeding symptoms of these patients were identical to the symptoms described here. One patient, who had multiple myeloma and a monoclonal paraprotein with antibody specificity for G P IIIa, died of gastrointestinal hemorrhage." ' The therapeutic use of MoAbs against platelet membrane G P IIb-IIIa to prevent t h r o m b o~i s~~.~' creates a new acquired disorder of platelet function analogous to thrombasthenia. Studies on the infusion of these MoAbs have demonstrated the occupation of most platelet G P IIb-IIIa, and the expected inhibition of platelet a g g r e g a t i~n .~~. '~.~~. "~ Significant hemorrhagic complications have not been observed. The infrequency of spontaneous hemorrhage in patients with Glanzmann's thrombasthenia, particularly the apparent absence of intracranial hemorrhage without trauma, support the potential safety of this therapy for acute situations of limited duration. However, the therapeutic use of MoAbs to G P Ilb-IIIa in conjunction with thrombolytic agents may increase the risk for hemorrhagic complications.
Coagulation disorders. Thombasthenia and hemophilia (congenital factor VI11 or IX deficiency), a model for coagulation disorders, share some clinical features. Epistaxis in children is nearly universal in both diseases, gingival bleeding and purpura with minor trauma are very common, and bleeding into the central nervous system is very rare in both disorders, even before the era of effective transfusion treatment for hemophilia."7 Gastrointestinal hemorrhage and 
CONCLUSIONS
The nature of the bleeding symptoms is consistent in all patients with Glanzmann's thrombasthenia, and these symptoms can be used as a basis for understanding the clinical manifestations of platelet function disorders. The bleeding problems of thrombasthenia are distinct from the problems of patients with inherited disorders of blood coagulation. Based on these distinctions, a clinical assessment of patients who have acquired disorders of hemostasis, such as uremia, should assist the clinician in distinguishing bleeding due to defective platelet function from bleeding due to abnormal coagulation.
In contrast to the clearly defined nature of bleeding in thrombasthenia, the severity of bleeding is unpredictable. Truly spontaneous bleeding is uncommon, as most serious hemorrhagic episodes are the result of trauma or an exaggeration of physiologic bleeding. The severity of bleeding in thrombasthenia, in contrast to the experience in hemophilia, does not correlate with the severity of the platelet G P IIb-IIIa abnormality. Some patients with nearly absent G P IIb-IIIa have minimal bleeding problems, while severe and recurrent hemorrhage can occur in some patients who have substantial amounts of functional platelet G P IIb-IIIa. However, the importance of platelet G P IIb-IIIa for normal hemostasis is clear: patients with thrombasthenia can have serious hemorrhage while heterozygous subjects who have half normal levels of G P IIb-IIIa have no clinically significant bleeding. These clinical observations provide insight into the critical platelet concentration of G P IIb-IIIa required for normal platelet function.
With careful supportive care of patients with Glanzmann's thrombasthenia, many episodes of serious hemorrhage can be prevented, periods of recurrent bleeding can be controlled, and the prognosis for normal survival and an active life is excellent.
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